On March 18-19, 2013, NOTOCORD® will attend the Pluripotent stem cells: Applications for cardiovascular risk assessment workshop.
This event, sponsored by the HESI Cardiac Safety Committee and Safety Pharmacology Society will take place at the Amgen Research Center in Cambridge, MA (USA).
Discussions and presentations will focus on applications of stem cell-derived cardiomyocytes and future opportunities for stem cell-derived assay systems. The objective is to evaluate current and potential use of stem cell platforms and associated technologies in the cardiovascular (CV) risk assessment of pharmaceuticals and/or environmental chemicals.
The workshop will ask key questions to a group of international and multi-disciplinary scientists:
- What are the current approaches to applying and developing stem cell-derived cardiomyocytes assay platforms ?
- How can this technology be used to inform CV risk assessment or pathway evaluation now and where is the potential for new application in the future ?
- What additional standards or data may be needed to facilitate the use of these data for translational science decision-making ?
Stem cell-derived cardiomyocytes are of particular interest to Pluriomics (Netherlands), Multi Channel Systems ("MCS", Germany) and NOTOCORD® (France) who joined forces, know-how and innovation to launch the CardioXpress project, a new platform dedicated to the analysis of field potential on human pluripotent stem cells cardiomyocytes (hPSC-CM).
|In this project we aim to build disposable multi-well MEA (Micro Electrode Array) sensing plates with miniaturized wells for automated High Throughput Screening (HTS) assays based on highly characterized hPSC-CM.|
The main objective is to provide a fast, completely expandable turnkey system to get a mechanistic view of drug activity.
Records and analysis of hPSC-CM responses at different concentrations of potential drugs with multi-well micro-electrode arrays will be saved and analyzed online and offline with advanced techniques to predict the effects on cardiac electrical activity of one or similar groups of compounds.
If you want to know more about CardioXpress during the Workshop, come and meet us or have a look at the poster presented by Thomas Meyer (MCS) on Extracellular Field potential Recording from Pluripotent Stem Cell Derived Cardiomyocytes by Multiwell Microelectrode Arrays (MEA).
Cardiovascular risk assessment and safety pharmacology have been investigating embryonic (ES) and induced pluripotent stem cell (iPS) derived Cardiomyocytes as a novel assay model to investigate drug induced modulations on shape and duration of the cardiac action potential. Here we present an electrophysiological assay capable for automation and increased throughput. Microelectrode arrays enable long term culture and recording of stem cell derived Cardiomyocytes.
Up to 252 recording electrodes allow recording and stimulation of monolayers or clusters of ES or iPS derived cardiomyocytes. The use of 6, 9, 24 or 96 wells in parallel increases the throughput and enables the use of this technology for secondary screening.
In the CardioXpress we are developing a turnkey solution including cells, hardware and software to run an automated test on drugs modulating the electrophysiology of cardiomyocytes.We will present data from stem cell-derived cardiomyocytes from various suppliers and their response to typical tool compounds. We furthermore illustrate the capability of the assay for automation and upscaling of the throughput and outline the concept of the CardioXpress project.
CardioXpress received the Eurostars label. The Eurostars Programme is powered by EUREKA and the European Community.